Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
CIML NK Cells With Venetoclax for AML
What the film says
This trial is for acute myeloid leukemia in which a small amount of disease remains after treatment, called measurable residual disease.
The idea: combine two treatments. Natural killer cells from a donor are trained in the lab with cytokines to become memory-like, and infused after lymphodepleting chemotherapy, with interleukin-2 injections. Venetoclax, a pill approved for this leukemia that blocks a protein called BCL-2, is taken alongside.
This is the first time the combination will be given to people. About 10 participants will be treated, with a hospital stay of up to four weeks. At Dana-Farber in Boston, Evan Chen leads this safety study.
Public record; not medical advice.
Sources behind this film
AML with measurable residual disease; Donor NK cells trained with cytokines to become memory-like; infused after lymphodepleting chemotherapy; with IL-2; Venetoclax: approved pill, blocks BCL-2, taken alongside; First time in people; about 10 participants; hospital stay up to four weeks (+1 more lines)
The drug
Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
Selective inhibitor of BCL-2 protein, 10, 50, or 100 mg tablets, via orally per standard-of-care.
This is an open-label, single center phase I trial combining Cytokine-induced memory-like natural killer (CIML NK) cell therapy with low-dose IL-2 and with venetoclax as consolidation therapy in acute myeloid leukemia (AML)with measurable residual disease or oligoblastic (< 20% blasts in the bone marrow) disease. This is the first time that CIML NK cells in combination with venetoclax will be given to humans. The U.S.
The study
The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid Leukemia (AML) with measurable residual disease or oligoblastic (< 20% blasts in the bone marrow) disease.
Names of the study therapies involved in this study are: * Lymphodepleting therapy with Fludarabine and Cyclophosphamide prior to CIML NK cell infusion * CIML NK (a cellular therapy) * IL-2 (a recombinant, human glycoprotein) * Venetoclax (a selective inhibitor of BCL-2 protein)
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.